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OBJECTIVE
Improved appetite control, possibly mediated by exaggerated gut peptide re-
sponses to eating, may contribute to weight loss after Roux-en-Y gastric bypass
(RYGB). This study compared brain responses to food ingestion between post-
RYGB (RYGB), normal weight (NW), and obese (Ob) unoperated subjects and
explored the role of gut peptide responses in RYGB.
RESEARCH DESIGN AND METHODS
Neuroimaging with [18F]-ﬂuorodeoxyglucose (FDG) positron emission tomogra-
phy was performed in 12 NW, 21 Ob, and 9 RYGB (18 6 13 months postsurgery)
subjects after an overnight fast, once FED (400 kcal mixedmeal), and once FASTED,
in random order. RYGB subjects repeated the studies with somatostatin infusion
and basal insulin replacement. Fullness, sickness, and postscan ad libitum meal
consumption were measured. Regional brain FDG uptake was compared using
statistical parametric mapping.
RESULTS
RYGB subjects had higher overall fullness and food-induced sickness and lower ad
libitum consumption. Brain responses to eating differed in the hypothalamus and
pituitary (exaggerated activation in RYGB), left medial orbital cortex (OC) (activa-
tion in RYGB, deactivation in NW), right dorsolateral frontal cortex (deactivation in
RYGB and NW, absent in Ob), and regions mapping to the default mode network
(exaggerated deactivation in RYGB). Somatostatin in RYGB reduced postprandial
gut peptide responses, sickness, and medial OC activation.
CONCLUSIONS
RYGB induces weight loss by augmenting normal brain responses to eating in
energy balance regions, restoring lost inhibitory control, and altering hedonic
responses. Altered postprandial gut peptide responses primarily mediate
changes in food-induced sickness and OC responses, likely to associate with
food avoidance.
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Roux-en-Y gastric bypass (RYGB) causes
weight loss, improves metabolic param-
eters, and reduces premature mortality
(1), with little evidence of restriction of
meal size or malabsorption (2). Sensations
of fullness are increased and food con-
sumption reduced (3,4). Understanding
changes in gut-to-brain signaling and brain
functionmediating theseeffectswould im-
proveunderstandingofweight control and
weight loss and may help develop novel
approaches to preventing and treating
obesity.
Altered gut-to-brain signaling after
RYGB may be mediated by gut peptides
(2). Glucagon-like peptide 1 (GLP-1) and
peptide YY (PYY) provide satiety signals.
RYGB increases their postprandial re-
sponses (2,5). The somatostatin analog
octreotide inhibits gut peptide secre-
tion, increases food intake, reduces sa-
tiety, and alters appetitive behavior
after RYGB (6,7).
In functional neuroimaging, surro-
gates are used to image regional brain
activity. In [18F]-ﬂuorodeoxyglucose
positron emission tomography (FDG-
PET), 18FDG is taken up as native glucose
and phosphorylated but not metabo-
lized further, accumulating within cells
(8). Brain FDG uptake correlates with
brain glucose metabolic rate, a marker
for brain activity. Comparing FDG-PET
images can therefore identify regions
of altered neuronal activation without
preconceived hypotheses. FDG-PET is
suited to imaging responses to slowly
changing physiological stimuli, such as
eating, but has not previously been
used for this. Other functional neuro
imaging modalities have been used to
investigate bariatric surgery (mainly
RYGB). Two dopamine receptor radioli-
gand PET studies, imaging only path-
ways using the ligand receptor, gave
conﬂicting results (9,10). Functional
MRI (fMRI) studies of responses to
food cues (rather than food ingestion)
have described reduced responses in re-
gions including the dorsal striatum (re-
ward), dorsolateral frontal cortex (DLFC)
(inhibitory control), precuneus, and
posterior cingulate in the fed state
(11,12); and, examining predeﬁned re-
gions of interest in the fasted state, in
the orbitofrontal cortex (OFC) and
amygdala, with evidence that octreotide
increases responses to food pictures
in the fed state without affecting full-
ness (7,13). One fMRI study reported
differences in response to oral glucose
between lean and obese subjects in the
hypothalamus, OFC, and somatosen-
sory cortex were partially reversed after
RYGB (4).
The aim of our study was to use FDG-
PET neuroimaging to identify regions
where brain responses to food ingestion
were different between post-RYGB
(RYGB), normal weight (NW), and obese
(Ob) unoperated subjects and investi-
gate the effect of using somatostatin
to inhibit gut peptide responses in
RYGB.
RESEARCH DESIGN AND METHODS
This research was approved by The
Royal Marsden Research Ethics Commit-
tee (08/H0801/152) and the Administra-
tion of Radioactive Substances Advisory
Committee (261-1945[23765]) and con-
ducted in accordance with the Declara-
tion of Helsinki (2008).
Participants and Recruitment
Right-handed adults were recruited
from obesity and bariatric surgery clinics
at King’s College Hospital and by e-mail
advertisement to students and staff at
King’s College London in three groups:
NW (BMI 20–25 kg/m2), Ob (BMI 30–
40 kg/m2), and RYGB ($3 months after
RYGB,$10% excess weight loss, current
BMI 25–40 kg/m2). Exclusion criteria in-
cluded contraindications to PET or MRI;
pregnancy, planning pregnancy, breast-
feeding; glucose .15 mmol/L during
75 g oral glucose tolerance test (NW
and Ob) or .11 mmol/L after 400 kcal
test meal (RYGB); glucose-lowering
medications (metformin permitted);
signiﬁcant brain disorder; use of psycho-
tropic medication.
Study Design
NW and Ob underwent ﬁve visits:
screening, 75 g oral glucose tolerance
test, two PET scanning visits (FASTED
and FED in random order), and a struc-
tural MRI brain scan (Philips Achieva
3.0 T scanner). RYGB underwent seven
visits: screening, 400 kcal test meal
(to determine capacity to consume
the meal and glucose response), four
PET scanning visits (placebo-FASTED,
placebo-FED, somatostatin-FASTED, and
somatostatin-FED in random order) and
a MRI brain scan. Subjects underwent a
dummy PET scan to diminish the effect of
the ﬁrst study (14).
FDG-PET Visits
FDG-PET visits were performed after
overnight fasting (.9 h), with water al-
lowed. Premenopausal women were
scanned in the ﬁrst 10 days of their cycle.
Arm intravenous catheters were sited. At
RYGB-somatostatin (RYGBss) visits, intra-
venous infusions of somatostatin (Actavis
or Eumedica, 0.1 mg/kg/min) (15,16)
and soluble human insulin (Actrapid,
in 4% autologous blood solution, 3.6
mU/m2body surface area/min; Novo Nordisk)
were started at 295 min and contin-
ued throughout. At RYGB-placebo
(RYGBpl) visits, 0.9% saline was infused.
Participants were blind to infusion con-
tent. If nausea developed, the somato-
statin infusion was reduced to 70%. If
venous plasma glucose (VPG) fell below
3.8 mmol/L, 20% glucose was infused to
maintain at 4–4.5 mmol/L.
For FED studies, subjects consumed a
400 kcal meal (Ha¨agen-Dazs vanilla ice
cream, fat 27 g, carbohydrate 32 g, pro-
tein 8 g) starting at25 min (NW and Ob
after 20-min rest, RYGB after 90-min in-
fusion). Three RYGB subjects unable to
consume the 400 kcal test meal were
given the amount tolerated (220–256
kcal). FDG (90 MBq) was injected intra-
venously 15 min after meal completion
in FED studies or equivalent time in
FASTED. Scanning commenced at +55 min
for 15 min (GE Discovery PET scanner,
15.8-cm axial ﬁeld of view; GE Medical
System). A low-dose computed tomog-
raphy brain scan was taken for attenu-
ation correction.
After each PET scan, subjects under-
went a 1-h ad libitum meal (6) in which
100 kcal ice cream was presented every
5 min, and subjects were instructed to
eat until they felt full. Subjects rated
fullness and sickness on visual analog
scales (VAS) at 2105 min (RYGB only),
27 min, +10 min, and +80 min (6). Ve-
nous blood was taken for insulin, GLP-1,
PYY, glucose-dependent insulinotropic
polypeptide (GIP), and glucagon at
2100 min (RYGB), 210 min, +30 min,
and +80 min and for glucose every 5 to
15 min. Plasma glucose was analyzed
immediately (YSI 2300 Stat analyzer).
Serum insulin was measured by chem-
iluminometric immunoassay (Advia
Centaur; Seimens) and gut peptides
GLP-1 and GIP by ELISA (Millipore)
and PYY and glucagon by radioimmu-
noassay (Millipore).
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Statistical Analysis
Statistical analyses used SPSS 22 soft-
ware (IBM). P # 0.05 was considered
signiﬁcant. Uncorrected P values are re-
ported. Continuous demographic data
were compared using one-way ANOVA
with post hoc comparisons, and categor-
ical data were compared using the
Fisher exact test. Mixed ANOVA was
used for analysis of VAS fullness, ad libi-
tum consumption, glucose, insulin, and
gut peptide data. For signiﬁcant interac-
tions between fed state and group, post
hoc comparisons for differences be-
tween groups in “FED effect” (FED mi-
nus FASTED) were performed using the
Fisher least signiﬁcant difference test. If
there was no interaction, main effects
of fed state and group are reported.
For the effect of somatostatin in
RYGB, within–within-subjects ANOVA
was used. Kruskal-Wallis and Wilcoxon
signed-rank tests were used to compare
nonnormally distributed sickness VAS.
FDG-PET Neuroimaging Analysis
Differences in FDG uptake between
scans were analyzed using Statistical
Parametric Mapping (SPM8) (www.ﬁl
.ion.ucl.ac.uk). Images were recon-
structed using the ﬁltered back-projection
algorithm. Images were acquired dy-
namically (15 3 1 min frames), and
frames showing motion were removed.
Images were spatially normalized to
Montreal Neurological Institute space
using each subject’s structural MRI.
MRI was not available in one NW and
one Ob subject, and mean PET images
were warped directly to Montreal Neu-
rological Institute space using the SPM
PET template. Images were smoothed
with a Gaussian kernel of 8 mm. The
cerebellum (Tziortzi atlas [17]) was ex-
cluded from further analysis. Global
differences in FDG uptake between
scans were removed by normalizing
voxel values to the mean gray-matter
value for each scan, scaled to 100. White
matter was masked out by including
voxels with values .60% mean and
gray-matter probability.30%. The pitu-
itary (deﬁned by MRI template) and hy-
pothalamus (Baroncini et al. [18]) were
masked in.
Images were compared to identify
clusters with signiﬁcant differences using
mixed ANOVA in SPM. For paired tests
(effect of fed state), clusters of voxels
were considered to show signiﬁcant
effect at voxel level P, 0.001 and clus-
ter level P, 0.05 (corrected for family-
wise error). For interactions between
fed state and group, clusters were con-
sidered to show signiﬁcant interaction
with cluster size .100 voxels and two
voxel level thresholds: P , 0.01 (liberal)
and P, 0.001 (stringent). Clusters were
localized using the Tziortzi atlas (17)
modiﬁed to include the pituitary and
hypothalamus.
For clusters identiﬁed in SPM with a
signiﬁcant interaction between fed
state and group, mean normalized voxel
values were extracted for each cluster
for all scans and food-evoked signal
change (FESC) (FED minus FASTED) was
calculated. For each cluster, the nature
of the difference in FESC between
groups was analyzed using the Fisher
least signiﬁcant difference test in SPSS
and the effects of somatostatin in RYGB
using paired t tests. Exploratory Spear-
man correlational analyses were per-
formed between FESC and ad libitum
meal consumption at the FASTED visit
(i.e., in the fasted state), FED effect
+10 min fullness and sickness, and FED
effect +30 min insulin and gut peptides.
RESULTS
Participants
The study included 12 NW, 21 Ob, and
9 RYGB subjects, with a mean 6 SD age
of 34.4 6 11.5 years (RYGB subjects
were older), with no signiﬁcant between-
group differences in sex, ethnicity, or sys-
tolic blood pressure (Table 1). RYGB
subjects were 18 6 12.6 months after
RYGB, having lost 30.9 6 8.5% of their
preoperative weight. BMI was not dif-
ferent between Ob and RYGB. HOMA2-
insulin resistance, reﬂecting fasting
insulin resistance (19), was not different
between NW and RYGB but was higher
in Ob. Medications included metformin
(one Ob, one RYGB), orlistat (two Ob,
one RYGB), and topiramate (one RYGB).
VAS for Fullness and Sickness
At27 min, VAS scores for fullness were
higher in RYGBpl than in NW or Ob,
which were not different (Fig. 1). Across
groups, fullness was higher in FED ver-
sus FASTED at +10 and +80 min. The nu-
merically greater FED effect on fullness
at +10 min in RYGBpl did not reach sig-
niﬁcance (P = 0.14), although fullness
scores at +10minwere higher, irrespective
of fed state, in RYGBpl compared with
NW and Ob. Somatostatin had no sig-
niﬁcant effect on fullness at27 min or
on responses to food ingestion at +10
or +80 min.
VAS scores for sickness were higher
in NW versus RYGBpl at 27 min. At
+10 min, sickness was higher in FED ver-
sus FASTED in RYGBpl but not in NW or
Ob. Somatostatin was reduced in two
RYGB subjects due to nausea. Despite
this, sickness scores were higher with
somatostatin at 27 min. However, so-
matostatin attenuated the increase in
sickness at +10 min in FED versus
FASTED (median FED effect RYGBpl +26
points, RYGBss +5 points; P = 0.05).
Ad Libitum Meal
Subjects consumed less at FED versus
FASTED, with no signiﬁcant between-
group differences in the effect of the fed
state on the amount consumed (Fig. 1).
Regardless of fed state, RYGBpl consumed
less than NW and Ob. Ad libitum con-
sumption in RYGBpl was (mean 6 SE)
2726 38 kcal vs. 3716 99 kcal in RYGBss
(P = 0.27 for main effect of somatostatin).
Glucose, Insulin, and Gut Peptides
Mean VPG between 0 to +80 min was
higher in FED versus FASTED, with no
between-group differences (P = 0.214
for interaction, P , 0.001 for main ef-
fect fed state, and P = 0.166 for main
effect group): (mean 6 SD) NW-FASTED,
4.9 6 0.4 mmol/L; NW-FED, 5.1 6
0.5mmol/L;Ob-FASTED,5.060.3mmol/L;
Ob-FED, 5.560.6mmol/L; RYGBpl-FASTED
4.7 6 0.5 mmol/L; RYGBpl-FED, 5.2 6
0.9 mmol/L; RYGBss-FASTED, 4.3 6 0.3
mmol/L; and RYGBss-FED, 5.4 6 0.7
mmol/L. There was no difference between
somatostatin and insulin versus placebo
on the FED effect (P = 0.152 for interaction)
or VPG irrespective of fed state (P = 0.675
for main effect). The highest VPG was
7.9 mmol/L.
Insulin was higher at 210 min in Ob
versus NW or RYGBpl, and at +30 min in
FED versus FASTED across all groups (Fig.
2). Insulin was not different at +80 min
between NW and RYGBpl, but remained
higher in Ob, with a greater FED effect
and higher concentrations overall.
There were no between-group differ-
ences inGLP-1, PYY, GIP (Fig. 2) or glucagon
(not shown) at 210 min. Between-group
differences were found in FED effect on
GLP-1 and PYY at +30 and +80 min, which
were larger in RYGBpl than in NW or Ob.
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GLP-1 was higher in FED versus FASTED
at +30 and +80 min in all groups (not sig-
niﬁcant in NW +30min). The FED effect on
PYY was small in NW and Ob and statisti-
cally signiﬁcant only in NW at +80min. GIP
was higher in FED versus FASTED at
+30 min, with no between-group differ-
ences, and remained higher in all groups
at +80 min, with a smaller FED effect in
RYGBpl. Glucagonwas higher in FED versus
FASTED at +30 min, with no between-
group differences in the FED effect and
no between-state or between-group dif-
ferences by +80 min.
Somatostatin with insulin in RYGB
achieved no signiﬁcant difference in in-
sulin between placebo and somato-
statin at210 min (85 min into infusions).
GLP-1, PYY, GIP, and glucagon were
lower with somatostatin at 210 min.
Somatostatin abolished insulin, GLP-1,
PYY, GIP, and glucagon responses to
food ingestion.
FDG-PET Neuroimaging
SPM analysis for the main effect of the
fed state across groups showed a single
large cluster (K) where FDG uptake was
higher in FED versus FASTED and ﬁve
clusters (L-P) where FDG uptake was
lower in FED versus FASTED (Fig. 3).
Cluster K (17,485 voxels) included the
hypothalamus, ventral cingulate subcal-
losal gyrus, anterior cingulate gyrus, bi-
lateral ventral striatum, globus pallidus,
temporal thalamus, insular cortex, or-
bital cortex (OC), extensive regions in
the temporal lobes (including amyg-
dala and hippocampus), and midbrain,
pons, and medulla (Supplementary
Table 1).
Two FED,FASTED clusters (L, 5,079
voxels; M, 4,571 voxels) included bilat-
eral anterior and posterior DLFC, ex-
tending into bilateral precentral gyrus,
bilateral frontal operculum, and right
lateral OC. Cluster N (388 voxels) in-
cluded anterior cingulate gyrus and dor-
sal anterior cingulate gyrus. Clusters O
(19,248 voxels) and P (200 voxels) in-
cluded posterior cingulate gyrus, bilat-
eral precuneus, and cuneus, extending
posteriorly to include bilateral calcarine
cortex, lingual gyrus, occipital pole, and
occipital fusiform gyrus and laterally
to include bilateral parietal lobule, an-
gular gyrus, supramarginal gyrus, parietal
operculum, central operculum (right), and
posterior temporal cortex (Supplementary
Table 2).
SPM analysis for interaction between
fed state and group showed 10 clusters
(A–J, voxel level P , 0.01, cluster size
threshold 100 voxels) (Supplementary
Fig. 3 and Supplementary Table 4). A
more stringent statistical threshold
(voxel level P , 0.001) showed three
clusters corresponding to clusters C, F,
and G (data not shown). Including age
as a covariate did not materially affect
the interaction clusters identiﬁed (data
not shown). For clusters A–J, FESC in NW,
Ob, and RYGBpl are shown in Fig. 4 (repre-
sentative clusters) and in Supplementary
Fig. 5 (numerical data are reported in
Supplementary Table 4). In E (hypothal-
amus) and F (pituitary), FESC was larger
in RYGBpl than in NW or Ob, with no
difference between NW and Ob. In A,
C, and D (right DLFC, anterior medial
frontal cortex, medial and lateral OC,
frontal operculum, and insular cortex),
there was a similar negative FESC in NW
and RYGBpl, absent in Ob. In B (left me-
dial OC), there was a negative FESC in
NW, with small positive FESC in Ob and a
larger positive FESC in RYGBpl. In G, H,
Table 1—Participant characteristics
NW (n = 12) Ob (n = 21) RYGB (n = 9) P value Post hoc tests P value
Age, years 32.3 6 9.3 31.1 6 10.5 45.1 6 10.7 0.004** NW vs. Ob 0.730
NW vs. RYGBpl 0.007**
Ob vs. RYGBpl 0.001**
Sex
Female 9 (75) 19 (90.5) 8 (88.9) 0.522 d
Male 3 (25) 2 (9.5) 1 (11.1)
Ethnicity
White 11 (91.7) 14 (66.7) 5 (55.6) 0.395 d
Black 0 3 (14.3) 2 (22.2)
Other 1 (8.3) 4 (19.0) 2 (22.2)
BMI, kg/m2 22.3 6 1.4 34.1 6 2.6 34.0 6 3.3 ,0.001*** NW vs. Ob ,0.001***
NW vs. RYGBpl ,0.001***
Ob vs. RYGBpl 0.876
Waist circumference, cm 76.2 6 5.2 100.1 6 7.7 101.8 6 11.5 ,0.001*** NW vs. Ob ,0.001***
NW vs. RYGBpl ,0.001***
Ob vs. RYGBpl 0.614
HOMA2-IR 0.68 6 0.18 2.09 6 1.03 0.84 6 0.30 ,0.001*** NW vs. Ob ,0.001***
NW vs. RYGBpl 0.637
Ob vs. RYGBpl ,0.001***
Blood pressure, mmHg
Systolic 114 6 10 124 6 15 121 6 10 0.123 d
Diastolic 71 6 7 78 6 10 78 6 5 0.040* NW vs. Ob 0.014*
NW vs. RYGBpl 0.064
Ob vs. RYGBpl 0.827
Continuous data are shown as the mean 6 SD and categorical data as n (%). HOMA2-IR, HOMA-insulin resistance (19). *P , 0.05. **P , 0.01.
***P , 0.001.
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and I (posterior cingulate gyrus, bilateral
precuneus, angular gyrus, occipital pole,
right cuneus, posterior superior and
middle temporal gyri, and left parietal
lobule), there was a larger negative
FESC in RYGBpl than in both NW and
Ob, with no difference between NW and
Ob (G and I) or larger negative FESC in
NW than in Ob (H). In cluster J (lingual
gyrus), FESC was positive in NW and
negative in Ob and RYGBpl.
For each cluster where there was a sig-
niﬁcant difference in responses to food
ingestion among the three groups,
FESC was calculated for RYGBss and
compared with RYGBpl (Fig. 4 and
Supplementary Fig. 5). In cluster B (left
medial OC), somatostatin abolished the
positive FESC seen in RYGBpl. Somato-
statin had no effect on FESC else-
where.
Exploratory Correlational Analyses
Exploratory correlational analyses were
performed for clusters A–J (Supplemen-
tary Tables 6–8). These analyses should
be viewedwith caution. Analyses includ-
ing all subjects were required to achieve
sufﬁcient power to detect even strong
correlations; therefore, weaker correla-
tions may have been missed, and there
is a potential effect of group separation.
Positive correlations were found be-
tween FESC and ad libitum consumption
in the fasted state in NW in cluster C
(rs = 0.910, P, 0.001), and across all sub-
jects in clusters A (rs = 0.378, P = 0.014),
G (rs = 0.461, P = 0.002), H (rs = 0.640,
P, 0.001), and I (rs = 0.662, P, 0.001),
with greater deactivation associated
with lower ad libitum consumption.
Negative correlations were found across
all subjects in clusters E (rs = 20.596,
P , 0.001) and F (rs = 20.539, P ,
0.001), with greater activation associated
with lower ad libitum consumption.
VAS scores showed signiﬁcant nega-
tive correlations between FESC and FED
effect fullness in cluster I (rs = 20.331,
P = 0.034) and FED effect sickness in
cluster G (rs = 20.321, P = 0.041).
In cluster B, there were signiﬁcant
positive correlations between FESC and
FED effect insulin (rs = 0.472, P = 0.015),
GLP-1 (rs = 0.708, P , 0.001), and PYY
(rs = 0.468, P = 0.018). In cluster E, there
was a signiﬁcant positive correlation be-
tween FESC and FED effect GLP-1 (rs =
0.632, P = 0.001) and in cluster F between
FESC and FED effect GLP-1 (rs = 0.709,
P , 0.001) and PYY (rs = 0.562, P =
0.003). Signiﬁcant negative correlations
between FESC and FED effect GLP-1
were found in clusters G (rs = 20.725,
P , 0.001), H (rs = 20.729, P , 0.001),
and I (rs = 20.662, P , 0.001).
Figure 1—Effect of food ingestion on fullness (A), sickness (C), and ad libitummeal consumption
(E) and the effect of somatostatin in RYGB (B,D, and F). For each parameter, the left panel shows
data for NW,Ob, and RYGBpl and the right panel shows the effect of somatostatin in RYGB. ForA,
C, and E, signiﬁcant interactions between fed state and group are shown as #P , 0.05, with
signiﬁcant post hoc comparisons for difference in FED effect shown as b, NW vs. RYGBpl, and c,
Ob vs. RYGBpl. If no interaction, main effect of fed state is shown as ***P , 0.001 and main
effect of group as †P, 0.05 and ††P, 0.01, with signiﬁcant post hoc comparisons indicated as
above and in E by P values. For B, D, and F, signiﬁcant interactions between fed state and
somatostatin in RYGB are shown as ǂP , 0.05. If no interaction, main effect of fed state
is shown as *P , 0.05 and ***P , 0.001, and the main effect of somatostatin is shown as
¶P , 0.05.
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CONCLUSIONS
Using imaging techniques that identify
differences in regional brain activation
independent of prior hypotheses and a
protocol that examines the response to
food ingestion per se, we have shown an
effect of RYGB on the response to inges-
tion of a 400 kcal meal in brain regions
subserving signal processing relating to
food ingestion and energy balance (hy-
pothalamus), reward evaluation (medial
OC), inhibitory control (DLFC), and the
default mode network (DMN). Our con-
trol subjects were NW and Ob adults,
the latter matched for BMI to RYGB sub-
jects, allowing us to investigate effects
of obesity.
The RYGB group showed normal fast-
ing insulin sensitivity. The meal size,
chosen to be tolerable after RYGB, was
sufﬁcient in all groups to affect fullness,
eating behavior, and gut peptides for at
least the duration of the FDG-PET scan-
ning. The physiological data from our
RYGB group are consistent with the lit-
erature, with higher fullness, reduced ad
libitum consumption (3), and exagger-
ated postprandial GLP-1 and PYY re-
sponses (5,20).
Regional brain responses to food in-
gestionwere extensive in regions known
to be involved in central regulation of
food intake (21). FDG uptake increased,
reﬂecting activation, in the hypothala-
mus and brainstem (signal processing
relating to food ingestion and energy
balance); insula (interoception); ventral
striatum, globus pallidus, OC, ventral
cingulate subcallosal gyrus, anterior cin-
gulate gyrus, amygdala, and hippocam-
pus (reward); and in the temporal lobes.
FDG uptake decreased, reﬂecting deac-
tivation, in bilateral DLFC (inhibitory
control), anterior cingulate gyrus, and a
large posterior cluster. The consistency of
these regions with those identiﬁed in pre-
vious functional neuroimaging studies in
NW individuals investigating response to
food ingestion (22–25) or effect of food
ingestion on the response to food cues
(26–29) demonstrates the utility of FDG-
PET in imaging responses to food inges-
tion. The activation in the temporal lobes
and deactivation in the posterior cluster
were unexpected. The latter is compatible
with the structures of the DMN (30).
Hypothalamic and pituitary activation
to food ingestion was exaggerated after
RYGB, suggesting that food ingestion
Figure 2—Effect of food ingestion on insulin (A), GLP-1 (C), PYY (E), and GIP (G) and the effect of
somatostatin in RYGB (B,D, F, andH). For each parameter, the left panel showsdata for NW,Ob, and
RYGBpl and the right panel shows the effect of somatostatin in RYGB. ForA,C, E, andG sampleswere
obtained at +30 min in 6 of 12 NW, 11 of 21 Ob, and 9 of 9 RYGBpl subjects; therefore, faint
connecting lines are used for NW and Ob. Signiﬁcant interactions between fed state and group
are shown as #P, 0.05, ##P, 0.01, and ###P, 0.001, with signiﬁcant post hoc comparisons for
difference in FED effect shown as a, NW vs. Ob; b, NW vs. RYGBpl; and c, Ob vs. RYGBpl. If no
interaction,main effect of fed state is shownas ***P, 0.001, and themain effect of group is shown
as †††P , 0.001, with signiﬁcant post hoc comparisons indicated as above. For B, D, F, and H,
signiﬁcant interactions between fed state and somatostatin in RYGB are shown as ǂǂP, 0.01. If no
interaction, themain effect of the fed state is shownas *P, 0.05 (no instances), and themain effect
of somatostatin is shown as ¶¶P, 0.01 and ¶¶¶P, 0.001.
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represents a greater physiological stimulus
after RYGB. The exploratory analyses sug-
gest correlation between activation in
these regions and limitationof food intake.
The only other study looking at brain re-
sponses to nutrient ingestion after RYGB
showed partial restoration of hypotha-
lamic responses from the obese toward
lean (4). Discrepancies in difference pat-
terns may relate to our use of a mixed
meal versus a pure glucose stimulus.
Our RYGB subjects showed activation
in the left medial OC versus deactivation
in NW control subjects. The above study
also showed differences in OC after
RYGB (4). The medial OC is involved in
evaluation of reward, and the pattern in
our study is consistent with pleasant
sensation in response to eating in NW
subjects versus unpleasant sensation
after RYGB.
Our data showed deactivation in right
DLFC in NW and RYGB subjects, absent
from the unoperated Ob subjects. The
correlational data in our NW subjects
supports an association between DLFC
deactivation and inhibitory control of
food intake. Attenuated DLFC responses
to food ingestion in Ob versus lean sub-
jects in [15O]-water PET studies were in-
terpreted as loss of inhibitory control
(31). Changes in response to food cues
have been described in DLFC after RYGB
(11,12) but not in response to nutrient
ingestion. Our data are consistent with
loss of the normal “stop eating” signal in
obesity and/or insulin resistance, re-
stored after RYGB and with clinical ob-
servations of restored inhibitory control
after RYGB, suggesting altered DLFC ac-
tivity after RYGB may contribute to
weight loss.
Our data showed exaggerated deacti-
vation in regions mapping to the DMN in
RYGB. These changes are consistent
with the response to eating being a
greater brain “task” after RYGB. Alterna-
tively, RYGB may reduce effects of previ-
ous eating experience. The exploratory
analyses suggest correlation between
deactivation in these regions and limita-
tion of food intake. There is some evi-
dence for an effect of RYGB on DMN
regions (4,11,12).
Apart from the OC, our data showed
loss of normal responses in obesity, re-
stored after RYGB, or exaggeration of
normal responses after RYGB. This is
consistent with data showing fMRI re-
sponses to oral glucose revert toward
normal after RYGB (4). Studies looking
at food cues generally ﬁnd greater re-
sponsivity to food cues in the obese at-
tenuated after RYGB (11–13,32–34).
Discrepancies may relate to differences
between food cues and food ingestion
or represent activation/deactivation of
stimulatory/inhibitory pathways in func-
tionally similar brain regions.
Somatostatin in RYGB suppressed
basal (fasting) GLP-1, PYY, GIP, and glu-
cagon and abolished postprandial pep-
tide responses, and concomitant insulin
infusion successfully replaced basal in-
sulin. Although postprandial sickness
was attenuated by somatostatin, full-
ness and ad libitum consumption did
not change signiﬁcantly. Previous stud-
ies found octreotide (without basal in-
sulin replacement) reduced the effect of
food ingestion on fullness and increased
Figure 3—Regional brain responses to food ingestion across all subjects. Cluster map of FED vs. FASTED (voxel level P, 0.001 and cluster level P, 0.05,
corrected for family-wise error) mapped on to a standard MRI brain for localization. The orange cluster is FED.FASTED (cluster K) and blue clusters are
FED,FASTED (clusters L, M, N, O, and P).
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ad libitum consumption after RYGB
(6,35). There may be differences in the
effects of octreotide and somatostatin.
Octreotide may have a direct action on
the brain (36). However, Goldstone et al.
(7) found no direct effect of octreotide
on food reward behaviors in NW subjects
or, when given with insulin, on postpran-
dial hunger or fullness after RYGB. Insulin
reduces food intake (37–39), albeit at
higher concentrations, and regional differ-
ences in brain FDG uptake were found in
reward regions with somatostatin with
versus without low-dose insulin infusion
(15), suggesting absence of basal insulin
may be important.
Of the 10 clusters where differences
between groups in brain response to
food ingestion were identiﬁed, somato-
statin only impacted in cluster B, the left
medial OC, where it abolished the acti-
vation seen after RYGB (not seen in NW
or Ob subjects). In exploratory correla-
tional analyses, this was the only cluster
where activation correlated with in-
crease in insulin, GLP-1, and PYY. These
data suggest gut peptides may mediate
the altered OC response after RYGB but
are not key mediators of the differences
seen in the hypothalamus, DLFC, or DMN.
Postprandial sickness in RYGB subjects,
also attenuated with somatostatin, may
be part of a food-avoidance response to
calorie-dense meals mediated by exag-
gerated gut peptide responses.
In summary, the RYGB group studied
here showed expected increased full-
ness, reduced food consumption, and
exaggerated postprandial GLP-1 and
PYY responses. Differences in brain re-
sponses to food ingestion were exaggera-
tion of normal hypothalamic activation,
consistent with food ingestion being a
greater physiological stimulus; reversed
responses in the left medial OC, consistent
with unpleasant, rather thanpleasant, sen-
sation; restoration of normal responses in
inhibitory control regions, lost in obesity;
and exaggerated deactivation in DMN,
consistent with food ingestion being a
greater task. These changes in brain re-
sponses would be expected to contribute
to weight loss. The somatostatin data sug-
gest exaggerated gut peptide responses
after RYGB mediate changes in medial
OC activity and in postprandial nausea
but may not be the major mediator of in-
creased fullness and reduced food inges-
tion and do not mediate the other
differences in brain responses to food
ingestion after RYGB.
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